Its therapeutic potential is further validated in orthotopic cancer models, where combining ST80 treatment with the FDA-approved anti–hPD-L1 antibody, durvalumab, demonstrated enhanced suppression of tumor growth and prolonged survival without evident toxic effects (3). Here, CD274 is linked to cancer.